Clinical Trials Sponsored by Beijing Novartis Pharma

Total 143 results

Peking University
Beijing Novartis Pharma

Completed

Clinical Pathway for Alzheimer's Disease in China (CPAD)

Dementia | Mild Cognitive Impairment | Alzheimer's Disease

China
Beijing Anzhen Hospital
Novartis

Unknown

Fluvastatin AmelIorates aTHerosclerosis Study (FAITH)

Atherosclerosis | Coronary Heart Disease

China
Novartis Pharmaceuticals
Roche Pharma AG

Completed

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Adenocarcinoma | Carcinoma | Renal Cell | Nephroid Carcinoma | Hypernephroid

Belgium, Italy, Spain, United Kingdom, Germany, Taiwan, Turkey, Egypt, Hong Kong, Russian Federation, Switzerland, Thailand, France, Netherlands, Korea, Republic of, Brazil, United States, Czech Republic, South Africa, Hungary, ...
Novartis
Novartis Vaccines; Chiron s.r.l. Beijing Representative Office

Completed

Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years)

Influenza

China
Novartis Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

Renal Transplantation
Novartis Pharmaceuticals
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy (STRIDE-PD)

Parkinson's Disease

United States, Switzerland, Germany, Finland, Greece, Italy, Spain, United Kingdom, Canada, France, Turkey, Belgium, Sweden, Austria
Novartis Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation

Completed

Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Spain, United States, Belgium, Germany, Italy, Israel, Australia, France, United Kingdom, Netherlands, Czechia, Japan, Canada, Greece, Poland
Novartis
Mitsubishi Tanabe Pharma Corporation

Completed

An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis

Multiple Sclerosis

Japan
Novartis
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)

Multiple Sclerosis

Japan
Teijin Pharma Limited

Completed

A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR) (J-REPAIR)

Acute Ischemic Stroke

Japan
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

Chronic Primary Immune Thrombocytopenia (ITP)

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject

Hepatic Impairment

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (ICC)

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Advanced Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Cholangiocarcinoma | Urothelial Carcinoma

Australia, United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-022 in Patients With R/R DLBCL (DLBCL)

Diffuse Large B Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Clinical Study of ICP-192 in Solid Tumors Patients

Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia Refractory

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Hematoma

China
InnoCare Pharma Inc.
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluating Different Doses of Orelabrutinib in MCL

Mantle Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Not yet recruiting

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Hematologic Malignancies

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma

Relapsed/Refractory Marginal Zone Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

The Study of ICP-248 in Patients With Mature B-cell Malignancies

Hematological Malignancies

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies

Advanced Solid Tumors and Hematologic Malignancies

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

DLBCL

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis

Psoriasis

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-033 in Patients With Advanced Solid Tumors

Patients With Advanced Solid Tumors

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma (BELIEVE-01)

Diffuse Large B Cell Lymphoma (DLBCL)

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

Bladder Urothelial Cancer

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Part 1：r/r B-cell Malignancies | Part 2：B-cell Malignancies

United States, Poland, Israel, Ukraine
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL

PCNSL | Secondary Central Nervous System Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects

Healthy Subjects

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study to Evaluate ICP-022 in Patients With CLL/ SLL

CLL/SLL

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

Study of ICP-105 in Solid Tumors Patients

Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Phase 2 Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

Advanced Solid Tumors Harboring NTRK Fusion | Primary Central Nervous System Tumors Harboring NTRK Fusion

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus, SLE

China
Beijing InnoCare Pharma Tech Co., Ltd.

Not yet recruiting

A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Patients With Advanced Solid Tumors

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia

Primary Immune Thrombocytopenia

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

Treatment-naїve Mantle Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

Solid Tumors

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

MZL

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

Mantle Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis

China, United States, Ukraine, Poland
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

Healthy Subject

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

China

Clinical Trials Sponsored by Beijing Novartis Pharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations